Reports
Sale
Global HUMIRA (Adalimumab) drug Market Size: By Indication: Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis, Psoriatic Arthritis, Others; By Type; By Dosage Strength; By Drug Type; By Route of Administration; By Distribution Channels; Regional Analysis; Supplier Landscape; 2024-2032
Global HUMIRA (Adalimumab) drug Market Outlook
The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2024-2032, driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment. The market is projected to grow at a CAGR of 1% during the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
HUMIRA (Adalimumab) Drug Market: Introduction
The global HUMIRA (Adalimumab) drug market is a rapidly growing market that provides treatment for various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by suppressing the immune system and reducing inflammation. It is a widely used drug and is considered as a first-line treatment option for many autoimmune diseases. The increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment are the key drivers of the market.
Expert Market Research has released a comprehensive report on the global HUMIRA (Adalimumab) drug market, which provides an in-depth analysis of the market and its segments. HUMIRA is a widely used drug for the treatment of various autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The report covers the market for HUMIRA and provides a detailed analysis of the market size, growth, and trends. The market is highly competitive with several key players involved in the market, focusing on developing new drugs and therapies to strengthen their position in the market.
HUMIRA (Adalimumab) Drug Market- Application and Usage
The global HUMIRA (Adalimumab) drug market is used for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by targeting and reducing the activity of a specific protein called tumor necrosis factor-alpha (TNF-alpha) that is involved in causing inflammation in the body. The drug is administered subcutaneously or intravenously, depending on the condition being treated.
Rheumatoid arthritis is one of the primary applications of HUMIRA, and it is widely used as a first-line treatment option for this condition. It is also used for the treatment of psoriasis, which is a chronic skin condition characterized by red, scaly patches on the skin. HUMIRA can provide relief from the symptoms of psoriasis by reducing inflammation in the skin.
In addition to rheumatoid arthritis and psoriasis, HUMIRA is also used for the treatment of Crohn's disease and ulcerative colitis. These are chronic inflammatory bowel diseases that affect the digestive system. HUMIRA can help reduce inflammation in the digestive tract and improve symptoms such as abdominal pain, diarrhea, and rectal bleeding.
HUMIRA (ADALIMUMAB) Drug Market Segmentations
The market can be categorised into indication, type, dosage strength, drug type, distribution channel, and route of administration.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Indication
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Chronic Plaque Psoriasis
- Crohn’s Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Others
Market Breakup by Type
- Biologics
- Biosimilars
- Adalimumab-ATTO
- Adalimumab-BWWD
- Adalimumab-ADBM
- Adalimumab-ADAZ
- Adalimumab-FKJP
- Adalimumab-AFZB
- Others
Market Breakup by Dosage Strength
- 40MG/0.4ML
- 80MG/0.8ML
- 20MG/0.4ML
- 10MG/0.1ML
- Others
Market Breakup by Drug Type
- Branded
- Generics
- Amjevita
- Hyrimoz
- Hulio
- Others
Market Breakup by Distribution Channels
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Route of Administration
- Parenteral
- Oral
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
HUMIRA (Adalimumab) drug Market Scenario
The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2024-2032. The market is driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment.
North America dominates the HUMIRA drug market, followed by Europe and the Asia Pacific region. The high prevalence of autoimmune diseases and the availability of advanced healthcare infrastructure are driving the growth of the market in North America. Europe is also a significant market for HUMIRA, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.
In addition, the COVID-19 pandemic has also affected the HUMIRA drug market, with disruptions in supply chain and manufacturing activities. However, the market is expected to recover in the post-pandemic period, driven by the increasing demand for effective treatments for autoimmune diseases.
Overall, the global HUMIRA (Adalimumab) drug market is expected to continue its growth trajectory during the forecast period, offering numerous opportunities for key players and investors in the industry.
Key Players in the Global HUMIRA (Adalimumab) drug Market
The report gives an in-depth analysis of the key players involved in the HUMIRA (Adalimumab) drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- AbbVie Inc.
- Amgen Inc.
- Fresenius Kabi AG
- Celltrion Healthcare Co Ltd
- Alvotech Ehf.
- Bio-Thera Solutions Ltd.
- Zydus Lifesciences Limited
- Hetero Healthcare Ltd.
- Innovent Biologics, Inc.
- Novartis International AG
- Reliance Life Sciences Pvt. Ltd.
- Samsung C&T Corporation
- Terumo Corp.
- Torrent Pharmaceuticals Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Type |
|
| Breakup by Dosage Strength |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 HUMIRA (Adalimumab Drug) Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Investment Scenarios
6.5 Regulatory Framework
6.5.1 Regulatory Overview
6.5.1.1 US FDA
6.5.1.2 EU EMA
6.5.1.3 INDIA CDSCO
6.5.1.4 JAPAN PMDA
6.5.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global HUMIRA (Adalimumab Drug) Market
8.1 Global HUMIRA (Adalimumab Drug) Market Overview
8.2 Global HUMIRA (Adalimumab Drug) Market Analysis
8.2.1 Market Overview
8.2.1.1 Global HUMIRA (Adalimumab Drug) Market Historical Value (2017-2023)
8.2.1.2 Global HUMIRA (Adalimumab Drug) Market Forecast Value (2024-2032)
8.3 Global HUMIRA (Adalimumab Drug) Market by Indication
8.3.1 Market Overview
8.3.1.1 Rheumatoid Arthritis
8.3.1.2 Ankylosing Spondylitis
8.3.1.3 Chronic Plaque Psoriasis
8.3.1.4 Crohn’s Disease
8.3.1.5 Ulcerative Colitis
8.3.1.6 Psoriatic Arthritis
8.3.1.7 Others
8.4 Global HUMIRA (Adalimumab Drug) Market by Type
8.4.1 Market Overview
8.4.1.1 Biologics
8.4.1.2 Biosimilars
8.4.1.2.1 Adalimumab-ATTO
8.4.1.2.2 Adalimumab-BWWD
8.4.1.2.3 Adalimumab-ADBM
8.4.1.2.4 Adalimumab-ADAZ
8.4.1.2.5 Adalimumab-FKJP
8.4.1.2.6 Adalimumab-AFZB
8.4.1.2.7 Others
8.5 Global HUMIRA (Adalimumab Drug) Market by Dosage Strength
8.5.1 Market Overview
8.5.1.1 40MG/0.4ML
8.5.1.2 80MG/0.8ML
8.5.1.3 20MG/0.4ML
8.5.1.4 10MG/0.1ML
8.5.1.5 Others
8.6 Global HUMIRA (Adalimumab Drug) Market by Drug Type
8.6.1 Market Overview
8.6.1.1 Branded
8.6.1.2 Generics
8.6.1.2.1 Amjevita
8.6.1.2.2 Hyrimoz
8.6.1.2.3 Hulio
8.6.1.2.4 Others
8.7 Global HUMIRA (Adalimumab Drug) Market by Route of Administration
8.7.1 Market Overview
8.7.1.1 Parenteral
8.7.1.2 Oral
8.7.1.3 Others
8.8 Global HUMIRA (Adalimumab Drug) Market by Distribution Channels
8.8.1 Market Overview
8.8.1.1 Hospital Based Pharmacies
8.8.1.2 Online Pharmacies
8.8.1.3 Retail Pharmacies
8.9 Global HUMIRA (Adalimumab Drug) Market by Region
8.9.1 Market Overview
8.9.1.1 North America
8.9.1.2 Europe
8.9.1.3 Asia Pacific
8.9.1.4 Latin America
8.9.1.5 Middle East and Africa
9 North America HUMIRA (Adalimumab Drug) Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe HUMIRA (Adalimumab Drug) Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific HUMIRA (Adalimumab Drug) Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America HUMIRA (Adalimumab Drug) Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa HUMIRA (Adalimumab Drug) Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global HUMIRA (Adalimumab Drug) Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter’s Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 AbbVie Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Amgen Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Fresenius Kabi AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Celltrion Healthcare Co Ltd
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Alvotech Ehf.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Bio-Thera Solutions Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Zydus Lifesciences Limited
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Hetero Healthcare Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Innovent Biologics, Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Novartis International AG (Sandoz)
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Reliance Life Sciences Pvt. Ltd.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Samsung C&T Corporation
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Terumo Corp.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Torrent Pharmaceuticals Ltd.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global HUMIRA (Adalimumab) Drug Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The prevalence rate of global HUMIRA (Adalimumab drug) market is likely to grow at a CAGR of 1% during the forecast period of 2024-2032.
Asia Pacific region has the highest growth rate in the HUMIRA (Adalimumab drug) market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
North America dominated the HUMIRA (Adalimumab drug) market and is expected to grow during the forecast period due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
AbbVie Inc., Amgen Inc., Fresenius Kabi AG, Celltrion Healthcare Co Ltd, Alvotech Ehf., Bio-Thera Solutions Ltd., Cadila Healthcare Ltd., Hetero Healthcare Ltd., Innovent Biologics, Inc., Novartis International AG are the key companies in the global HUMIRA (Adalimumab drug) market.
The factors stimulating the development of the market include increased government initiatives, optimal costs, and a rise in R&D expenditure in biopharmaceutical companies.
The high cost of clinical trials and research and development represents a major challenge for market participants. Despite heavy R&D spending, manufacturers must keep their products low, which limits growth opportunities in the HUMIRA market.
IBI303 and CT-P17 are the emerging drugs that will appear in the market
HUMIRA is a medicine used to treat ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ulcerative colitis, hidradenitis suppurativa and other diseases affecting the musculoskeletal system.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER